Literature DB >> 21986170

Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause.

Katrin Marquardt1, Heinz H Büttner, Ulf Broschewitz, Malte Barten, Volker Schneider.   

Abstract

OBJECTIVE: It was the aim of this study to determine the screening history of all invasive cervical carcinomas between 2004 and 2009 in one of the Federal States of Germany. STUDY
DESIGN: The pooled data sets of all in-state laboratories, corrected and supplemented by data of the State Cancer Registry, were used. The screening histories of all patients, their age and tumor types were collated and analyzed.
RESULTS: Of 617 patients with invasive carcinoma of the cervix, 373 (60%) had not had a cervical smear within the past 5 years. In 188 patients (31%), an incomplete screening history was found, whereas only 9% of women had participated regularly. In non-participants, late tumor stages (stage T1B and higher) were predominant and found in 86%. In contrast, in the group with regular screening histories more than half of all cases (54%) were microinvasive carcinomas (stage T1A) with excellent prognosis. Lack of follow-up or refusal of treatment by patients played a minor yet significant role.
CONCLUSIONS: Non-participation is still by far the most common reason for persistent cases of cervical carcinoma in the German screening program.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986170     DOI: 10.1159/000331811

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  10 in total

1.  Method comparison between Munich II and III nomenclature for Pap smear samples.

Authors:  Christoph Cirkel; Claudia Barop; Daniel A Beyer
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-11-02

2.  [Quality of conventional PAP smears. Quality assessment and motivation for improvement].

Authors:  P Regitnig; A Nader; H Wiener
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

3.  [Self-collection of test material. Supplement to cervical cancer screening].

Authors:  B R Mangold
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

4.  [Cervical cancer screening in Germany. Current status].

Authors:  V Schneider
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

5.  Systematic Comparison of Different Meta-analyses, Systematic Reviews and HTA Reports on Cervical Cancer Screening based on Cytology or HPV Test.

Authors:  M Jentschke; P Hillemanns
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

6.  Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study.

Authors:  Linda A Liang; Sylke R Zeissig; Gunther Schauberger; Sophie Merzweiler; Kathrin Radde; Sabine Fischbeck; Hans Ikenberg; Maria Blettner; Stefanie J Klug
Journal:  BMC Womens Health       Date:  2022-07-09       Impact factor: 2.742

7.  [Cervical cancer in Mecklenburg-Western Pomerania. Tumor stage, histological tumor type, age and screening participation of 985 patients].

Authors:  K Marquardt; M Stubbe; U Broschewitz
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

8.  Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions.

Authors:  Raquel Ibáñez; María Alejo; Neus Combalia; Xavier Tarroch; Josefina Autonell; Laia Codina; Montserrat Culubret; Francesc Xavier Bosch; Silvia de Sanjosé
Journal:  Biomed Res Int       Date:  2015-06-09       Impact factor: 3.411

9.  Effect of β-sitosterol on the expression of HPV E6 and p53 in cervical carcinoma cells.

Authors:  Dali Cheng; Zhiqiang Guo; Shulan Zhang
Journal:  Contemp Oncol (Pozn)       Date:  2015-03-26

10.  A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States.

Authors:  Rebecca Landy; Christopher Mathews; Michael Robertson; Charles L Wiggins; Yolanda J McDonald; Daniel W Goldberg; Isabel C Scarinci; Jack Cuzick; Peter D Sasieni; Cosette M Wheeler
Journal:  Gynecol Oncol       Date:  2020-09-22       Impact factor: 5.482

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.